» Articles » PMID: 29907113

Microorganisms Resistant to Conventional Antimicrobials in Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Overview
Journal Respir Res
Specialty Pulmonary Medicine
Date 2018 Jun 17
PMID 29907113
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Antimicrobial treatment for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) remains controversial. In some cases AECOPD are caused by microorganisms that are resistant to treatments recommended by guidelines. Our aims were: 1) identify the risk factors associated with infection by microorganisms resistant to conventional treatment (MRCT), 2) Compare the clinical characteristics and outcomes of patients with AECOPD resulting from MRCT against those with AECOPD from other causes.

Methods: We prospective analysed a cohort of patients admitted with severe AECOPD (2009 to 2015) who were assigned to three groups: patients with MRCT (those patients with germs resistant to antibiotics recommended in guidelines), patients with microorganisms sensitive to conventional antimicrobial treatment (MSCT), and patients with negative microbiology results who had not previously received antibiotics. Multinomial logistic regression analyses were used to examine the associations between microbial aetiology groups and risk factors. The association between LOS and risk factors was also tested in simple and multiple analyses, and similar inclusion criteria were applied for the linear regression analysis.

Results: Of the 451 patients admitted, 195 patients (43%) were included. Respiratory cultures were positive in 86(44%) and negative in 109(56%). MRCT were isolated in 34 cases (40%) and MSCT in 52 (60%). Patients with MRCT had more AECOPD in the previous year, received more antibiotic treatment in the previous three months, had more severe disease, higher dyspnoea and a positive respiratory culture in the previous year (mainly for Pseudomonas aeruginosa). The following conditions were independent factors for MRCT isolation: non-current smoker (odds ratio [OR] 4.19 [95% confidence interval [CI] 1.29-13.67], p = 0.017), ≥ 2 AECOPD or ≥ 1 admission for AECOPD in the previous year (OR 4.13 [95% CI 1.52-11.17], p = 0.005), C-reactive protein < 5 mg/dL; (OR 3.58 [95% CI 1.41-9.07], p = 0.007). Mortality rates were comparable at 30-days, one year and 3 years; however, patients in the MRCT group had longer hospital stays.

Conclusion: In conclusion, there are risk factors for resistant germs in AECOPD; however, the presence of these germs does not increase mortality. Patients with isolation of MRCT had longer length of stay.

Citing Articles

Reducing Hospital Readmissions in Chronic Obstructive Pulmonary Disease Patients: Current Treatments and Preventive Strategies.

Di Chiara C, Sartori G, Fantin A, Castaldo N, Crisafulli E Medicina (Kaunas). 2025; 61(1).

PMID: 39859079 PMC: 11766895. DOI: 10.3390/medicina61010097.


Trends in the Bacterial Prevalence and Antibiotic Resistance Patterns in the Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Hospitalized Patients in South India.

Ullah M, Malamardi S, Siddaiah J, A T, Prashant A, Vishwanath P Antibiotics (Basel). 2022; 11(11).

PMID: 36358232 PMC: 9686600. DOI: 10.3390/antibiotics11111577.


Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review.

Hurst J, Han M, Singh B, Sharma S, Kaur G, De Nigris E Respir Res. 2022; 23(1):213.

PMID: 35999538 PMC: 9396841. DOI: 10.1186/s12931-022-02123-5.


A Risk Prediction Model for Prolonged Length of Stay in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Retrospective Study of 225 Patients in a Single Center in Kunming, China.

Yang L, Li M, Shu J, Yang Y, Huang Q Med Sci Monit. 2022; 28:e934392.

PMID: 35136009 PMC: 8842644. DOI: 10.12659/MSM.934392.


Low APOA-1 Expression in Hepatocellular Carcinoma Patients Is Associated With DNA Methylation and Poor Overall Survival.

Guo Y, Huang B, Li R, Li J, Tian S, Peng C Front Genet. 2021; 12:760744.

PMID: 34790226 PMC: 8591198. DOI: 10.3389/fgene.2021.760744.


References
1.
Miravitlles M, Espinosa C, Martos J, Maldonado J, Gallego M . Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest. 1999; 116(1):40-6. DOI: 10.1378/chest.116.1.40. View

2.
Sagel S, Gibson R, Emerson J, McNamara S, Burns J, Wagener J . Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr. 2008; 154(2):183-8. PMC: 2654617. DOI: 10.1016/j.jpeds.2008.08.001. View

3.
Fernandez-Barat L, Ferrer M, De Rosa F, Gabarrus A, Esperatti M, Terraneo S . Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance. J Infect. 2016; 74(2):142-152. DOI: 10.1016/j.jinf.2016.11.008. View

4.
Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F . Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet. 2002; 358(9298):2020-5. DOI: 10.1016/S0140-6736(01)07097-0. View

5.
Brook I, Gober A . Recovery of potential pathogens and interfering bacteria in the nasopharynx of smokers and nonsmokers. Chest. 2005; 127(6):2072-5. DOI: 10.1378/chest.127.6.2072. View